NEW YORK--(BUSINESS WIRE)--Jan. 27, 2005--Goodkind Labaton Rudoff & Sucharow LLP and Schiffrin & Barroway, LLP, co-lead counsel for lead plaintiffs in a federal securities fraud action pending in California are seeking information about Maxim Pharmaceutical’s business practices during the time frame of November 11, 2002 through September 17, 2004 regarding the so-called success of its leading drug candidate, Ceplene (formerly called Maximine). The suit alleges that Maxim released fraudulent public statements regarding the prospects of FDA approval of Ceplene to treat advanced malignant melanoma patients with liver metastases.
